Switch theme
Sign up to access all valuation multiples
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers/software.
1994
228
LTM Revenue $73.6M
LTM EBITDA $22.8M
$351M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CellaVision has a last 12-month revenue of $73.6M and a last 12-month EBITDA of $22.8M.
In the most recent fiscal year, CellaVision achieved revenue of $71.8M and an EBITDA of $18.4M.
CellaVision expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CellaVision valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $67.3M | $71.8M | XXX | XXX | XXX |
| Gross Profit | $43.5M | $46.0M | XXX | XXX | XXX |
| Gross Margin | 65% | 64% | XXX | XXX | XXX |
| EBITDA | $20.6M | $18.4M | XXX | XXX | XXX |
| EBITDA Margin | 31% | 26% | XXX | XXX | XXX |
| Net Profit | $11.8M | $12.9M | XXX | XXX | XXX |
| Net Margin | 17% | 18% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, CellaVision's stock price is SEK 153 (or $15).
CellaVision has current market cap of SEK 3.7B (or $363M), and EV of SEK 3.5B (or $351M).
See CellaVision trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $351M | $363M | XXX | XXX | XXX | XXX | $0.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, CellaVision has market cap of $363M and EV of $351M.
CellaVision's trades at 4.8x LTM EV/Revenue multiple, and 15.4x LTM EBITDA.
Analysts estimate CellaVision's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CellaVision and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $351M | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | 19.1x | XXX | XXX | XXX |
| P/E | 26.0x | XXX | XXX | XXX |
| P/E/Growth | 1.2x | XXX | XXX | XXX |
| EV/FCF | 29.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCellaVision's NTM/LTM revenue growth is 10%
CellaVision's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, CellaVision's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CellaVision's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CellaVision and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 36% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 43% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CellaVision acquired XXX companies to date.
Last acquisition by CellaVision was XXXXXXXX, XXXXX XXXXX XXXXXX . CellaVision acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was CellaVision founded? | CellaVision was founded in 1994. |
| Where is CellaVision headquartered? | CellaVision is headquartered in Sweden. |
| How many employees does CellaVision have? | As of today, CellaVision has 228 employees. |
| Who is the CEO of CellaVision? | CellaVision's CEO is Dr. Simon Ostergaard, PhD. |
| Is CellaVision publicy listed? | Yes, CellaVision is a public company listed on STO. |
| What is the stock symbol of CellaVision? | CellaVision trades under CEVI ticker. |
| When did CellaVision go public? | CellaVision went public in 2007. |
| Who are competitors of CellaVision? | Similar companies to CellaVision include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of CellaVision? | CellaVision's current market cap is $363M |
| What is the current revenue of CellaVision? | CellaVision's last 12-month revenue is $73.6M. |
| What is the current EBITDA of CellaVision? | CellaVision's last 12-month EBITDA is $22.8M. |
| What is the current EV/Revenue multiple of CellaVision? | Current revenue multiple of CellaVision is 4.8x. |
| What is the current EV/EBITDA multiple of CellaVision? | Current EBITDA multiple of CellaVision is 15.4x. |
| What is the current revenue growth of CellaVision? | CellaVision revenue growth between 2023 and 2024 was 7%. |
| Is CellaVision profitable? | Yes, CellaVision is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
